Home / Meet Symeres at Drug Discovery & Development Europe 2026
Meet Symeres at Drug Discovery & Development Europe 2026
Symeres will be attending Discovery & Development Europe 2026, hosted by Oxford Global, where leaders from across drug discovery and development come together to share insights, explore new technologies, and build strategic partnerships.
During the event, we look forward to discussing how we can support your programs — whether you are progressing early discovery assets, addressing complex development challenges, or preparing for the next stages of CMC and IND-enabling activities.
If you’re attending Discovery & Development Europe, we would welcome the opportunity to meet and explore how Symeres’ integrated discovery and development capabilities can help move your programs forward efficiently and with reduced risk.
Who may benefit from meeting with Symeres
A conversation may be particularly valuable for:
• Biotech companies advancing discovery or early development programs and seeking integrated scientific support
• Pharmaceutical teams exploring partners for complex chemistry, ADME-Tox, or development challenges
• Organizations looking to accelerate timelines through flexible outsourcing strategies while maintaining scientific quality
• Teams working with complex or novel molecules that may benefit from specialist expertise across discovery and development
What we can discuss
Symeres partners with biotechnology and pharmaceutical companies across the small-molecule pathway, supporting programs from early discovery through development and into the clinic.
At Discovery & Development Europe, we would be pleased to discuss topics such as:
• Advancing discovery programs through medicinal chemistry and integrated ADME-Tox strategies
• Addressing complex challenges across chemistry, biology, and early development
• CMC strategy and planning for IND-enabling studies
• Drug substance development and manufacturing
• Integrated support from molecule to IND
Attending From Symeres
Goran Verspui, PhD
Head of Drug Development, Symeres
Goran Verspui is Head of Drug Development at Symeres, where he leads strategy and project delivery from clinical candidate nomination through to the supply of drug substance and drug product for clinical trials. He works closely with multidisciplinary teams across Symeres’ global sites to support efficient progression into the clinic.
With more than 20 years of experience in the pharmaceutical industry, Goran brings deep expertise in organic chemistry and process development, with a strong focus on large-scale synthesis, green chemistry, process safety, and product quality.
He is passionate about building high-performing teams and delivering practical, science-led solutions that help clients advance complex drug development programs with confidence.
Sam Ceusters
Head of Chemistry, SymeGold Screening Library, Symeres
Sam Ceusters is Head of Chemistry for the SymeGold Screening Library at Symeres, where he leads the development and expansion of the company’s proprietary small-molecule screening collection. He works closely with biotechnology and pharmaceutical partners to support hit identification and early drug discovery through high-quality screening compounds and scientific expertise.
With a background in medicinal chemistry and drug discovery, Sam combines scientific leadership with a strong focus on helping clients establish robust starting points for successful discovery programs. He regularly collaborates with research, business development, and marketing teams to showcase Symeres’ integrated drug discovery capabilities and support customers in accelerating their projects.
Tim Calvert, PhD
Head of Business Development – EU, Symeres
Tim Calvert is Head of Business Development – EU at Symeres, where he leads strategic engagement with biotechnology and pharmaceutical partners across drug discovery and development. In his role, Tim works closely with clients to understand their scientific and operational needs, helping connect them with Symeres’ integrated capabilities across chemistry, biology, ADME-Tox and CMC.
With a PhD background and extensive experience across the CRO/CDMO and biopharma sectors, Tim combines scientific understanding with commercial and operational expertise. Prior to joining Symeres, he held senior leadership roles at organizations including Thermo Fisher Scientific, Abzena and CL Biologics, where he supported the advancement of both novel and complex therapeutic programs.
Tim is passionate about building collaborative, transparent partnerships and helping clients navigate the challenges of progressing drug discovery and development programs efficiently from concept through to the clinic.
